Aldosterone as an Independent Factor in Cerebrovascular Damage

References

• Kuhlman D, Ragan C, Ferrebee JW, Atchley DW, Loeb RF. Toxic effects of deoxycorticosterone esters in dogs. Science 1939; 90: 496–497
   PubMedGoogle Scholar
• Webb RC, Bohr DF. What makes the pressure go up? A hypothesis. Hypertension 1981; 3: 160–165
   Web of Science ®Google Scholar
• Gomez-Sanchez EP. What is the role of the central nervous system in mineralocorticoid hypertension?. Am J Hypertens 1991; 4: 374–381
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez EP, Gomez-Sanchez CE. First there was one, then two … why more 11beta-hydroxysteroid dehydrogenases?. Endocrinology 1997; 138: 5087–5088
   PubMed Web of Science ®Google Scholar
• MacKenzie SM, Lai M, Clark CJ, Fraser R, Gomez-Sanchez CE, Seckl JR, Connell JM, Davies E. 11beta-hydroxylase and aldosterone synthase expression in fetal rat hippocampal neurons. J Mol Endocrinol 2002; 29: 319–325
   PubMedGoogle Scholar
• Ye P, Kenyon CJ, MacKenzie SM, Seckl JR, Fraser R, Connell JM, Davies E. Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 2003; 144: 3321–3328
   PubMed Web of Science ®Google Scholar
• Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983; 80: 6056–6060
   PubMed Web of Science ®Google Scholar
• Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994; 79: 480–484
   PubMed Web of Science ®Google Scholar
• Spencer RL, Young EA, Choo PH, McEwen BS. Adrenal steroid type I and type II receptor binding: Estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res 1990; 514: 37–48
   PubMed Web of Science ®Google Scholar
• de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 2000; 57: 1329–1336
   PubMed Web of Science ®Google Scholar
• Roland BL, Li KX, Funder JW. Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology 1995; 136: 4697–4700
   PubMed Web of Science ®Google Scholar
• Nyakas C, De Kloet ER, Veldhuis HD, Bohus B. Hippocampal corticosterone receptors and novelty-induced behavioral activity: Effect of kainic acid lesion in the hippocampus. Brain Res 1983; 288: 219–228
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 1990; 258: E649–E653
   PubMed Web of Science ®Google Scholar
• Buggy J, Fink GD, Haywood JR, Johnson AK, Brody MJ. Interruption of the maintenance phase of established hypertension by ablation of the anteroventral third ventricle (AV3V) in rats. Clin Exp Hypertens 1978–1979; 1: 337–353
   PubMed Web of Science ®Google Scholar
• Brody MJ, Varner KJ, Vasquez EC, Lewis SJ. Central nervous system and the pathogenesis of hypertension. Sites and mechanisms. Hypertension 1991; 18: III7–III12
   PubMedGoogle Scholar
• Sakai RR, Ma LY, Zhang DM, McEwen BS, Fluharty SJ. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology 1996; 64: 425–429
   PubMed Web of Science ®Google Scholar
• Sakai RR, Ma LY, Zhang DM, McEwen BS, Fluharty SJ. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology 1996; 64: 425–429
   PubMed Web of Science ®Google Scholar
• Kubo T, Hashimoto M. Effects of intraventricular and intraspinal 6-hydroxydopamine on blood pressure of DOCA-saline hypertensive rats. Arch Int Pharmacodyn Ther 1979; 238: 50–59
   PubMedGoogle Scholar
• Reid JL, Zivin JA, Kopin IJ. Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res 1975; 37: 569–579
   PubMed Web of Science ®Google Scholar
• Betz AJ. Sodium transport from blood to brain: Inhibition by furosemide and amiloride. J Neurochem 1983; 41: 1158–1164
   PubMed Web of Science ®Google Scholar
• Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertens 1993; 6: 487–495
   PubMed Web of Science ®Google Scholar
• Ritchie JM, Black JA, Waxman SG, Angelides KJ. Sodium channels in the cytoplasm of Schwann cells. Proc Natl Acad Sci USA 1990; 87: 9290–9294
   PubMed Web of Science ®Google Scholar
• Chassande O, Renard S, Barbry P, Lazdunski M. The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter. J Biol Chem 1994; 269: 14484–14489
   PubMed Web of Science ®Google Scholar
• Duc C, Farman N, Canessa CM, Bonvalet JP, Rossier BC. Cell-specific expression of epithelial sodium channel alpha, beta, and gamma subunits in aldosterone-responsive epithelia from the rat: Localization by in situ hybridization and immunocytochemistry. J Cell Biol 1994; 127: 1907–1921
   PubMed Web of Science ®Google Scholar
• Renard S, Lingueglia E, Voilley N, Lazdunski M, Barbry P. Biochemical analysis of the membrane topology of the amiloride-sensitive Na+ channel. J Biol Chem 1994; 269: 12981–12986
   PubMed Web of Science ®Google Scholar
• Smith PR, Saccomani G, Joe EH, Angelides KJ, Benos DJ. Amiloride-sensitive sodium channel is linked to the cytoskeleton in renal epithelial cells. Proc Natl Acad Sci USA 1991; 88: 6971–6975
   PubMed Web of Science ®Google Scholar
• Marver D. Models of aldosterone action on sodium transport: emerging concepts. Adv Exp Med Biol 1986; 196: 153–171
   PubMedGoogle Scholar
• Janiak PC, Lewis SJ, Brody M.J. Role of central mineralocorticoid binding sites in development of hypertension. Am J Physiol 1990; 259: R1025–R1034
   PubMed Web of Science ®Google Scholar
• Gavras H, Gavras I. Salt-induced hypertension: The interactive role of vasopressin and of the sympathetic nervous system. J Hypertens 1989; 7: 601–606
   PubMed Web of Science ®Google Scholar
• Berecek KH. Role of central vasopressin in cardiovascular regulation. J Cardiovasc Pharmacol 1986; 8: S76–S80
   PubMed Web of Science ®Google Scholar
• Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: A novel pathway for mineralocorticoid action. Am J Physiol 1992; 263: E974–E979
   PubMed Web of Science ®Google Scholar
• Sakai RR, McEwen BS, Fluharty SJ, Ma LY. The amygdala: Site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int 2000; 57: 1337–1345
   PubMed Web of Science ®Google Scholar
• Sakai RR, Nicolaidis S, Epstein AN. Salt appetite is suppressed by interference with angiotensin II and aldosterone. Am J Physiol 1986; 251: R762–R768
   PubMed Web of Science ®Google Scholar
• Osterziel KJ, Hanlein D, Willenbrock R, Eichhorn C, Luft F, Dietz R. Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure. Br Heart J 1995; 73: 517–522
   PubMedGoogle Scholar
• La Rovere MT, Bigger JT, Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators. Lancet 1998; 351: 478–484
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321
   PubMed Web of Science ®Google Scholar
• DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75–197
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats. Hypertension 1999; 33: 1201–1206
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats. Hypertension 2001; 38: 902–906
   PubMed Web of Science ®Google Scholar
• Janiak PC, Lewis SJ, Brody MJ. Role of central mineralocorticoid binding sites in development of hypertension. Am J Physiol 1990; 259: R1025–R1034
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez EP, Gomez-Sanchez CE. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione. Endocrinology 1986; 118: 2582–2587
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Bravo EL. Hypertensive mechanisms associated with centrally administered aldosterone in dogs. Hypertension 1988; 11: 750–753
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 1990; 258: E649–E653
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez EP. What is the role of the central nervous system in mineralocorticoid hypertension?. Am J Hypertens 1991; 4: 374–381
   PubMed Web of Science ®Google Scholar
• Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT, Jr. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol 2003; 14: 1990–1997
   PubMed Web of Science ®Google Scholar
• Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension 1998; 31: 451–458
   PubMed Web of Science ®Google Scholar
• Rocha R, Stier CT. Pathophysiological effects ofaldosterone in cardiovascular tissues. Endocrinolol Metab 2001; 12: 308–314
   PubMed Web of Science ®Google Scholar
• Smeda JS, Tkachenko O. Effects of diuretics on stroke development in Kyoto-Wistar stroke-prone spontaneously hypertensive rats. Clin Sci (Lond) 1991; 81: 335–340
   PubMed Web of Science ®Google Scholar
• Mac Leod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril treated hypertensive rats. Stroke 1997; 28: 1821–1829
   PubMed Web of Science ®Google Scholar
• Coyle P. Spatial relations of dorsal anastomoses and lesion border after middle cerebral artery occlusion. Stroke 1987; 18: 1133–1140
   PubMed Web of Science ®Google Scholar
• Resink TJ, Scott-Burden T, Baur U, Burgin M, Buhler FR. Enhanced responsiveness to angiotensin II in vascular smooth muscle cells from spontaneously hypertensive rats is not associated with alterations in protein kinase C. Hypertension 1989; 14: 293–303
   PubMed Web of Science ®Google Scholar
• Florian JA, Watts SW. Epidermal growth factor: A potent vasoconstrictor in experimental hypertension. Am J Physiol 1999; 276: H976–H983
   PubMed Web of Science ®Google Scholar
• Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 2001; 281: R944–R950
   PubMed Web of Science ®Google Scholar
• Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001; 38: 606–611
   PubMed Web of Science ®Google Scholar
• Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002; 87: 448–452
   PubMed Web of Science ®Google Scholar
• White PC. Aldosterone: Direct effects on and production by the heart. J Clin Endocrinol Metab 2003; 88: 2376–2383
   PubMed Web of Science ®Google Scholar
• Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–165
   PubMed Web of Science ®Google Scholar
• Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897–902
   PubMed Web of Science ®Google Scholar
• Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon R, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF, Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 83: 1045–1050
   Google Scholar
• Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471–1478
   PubMed Web of Science ®Google Scholar
• Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED, Jr, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877–885
   PubMed Web of Science ®Google Scholar
• Jeck T, Weisser B, Mengden T, Erdmenger L, Grune S, Vetter W. Primary aldosteronism: Difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands. Clin Invest 1994; 72: 979–984
   PubMedGoogle Scholar
• Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–1248
   PubMed Web of Science ®Google Scholar
• Sutherland DJA, Ruse JC, Laidlaw JC. Hypertension increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. J Can Med Assoc 1966; 95: 1109–1119
   PubMed Web of Science ®Google Scholar
• Litchfield WR, Coolidge C, Silva P, Lifton RP, Fallo F, Williams GH, Dluhy RG. Impaired potassium-stimulated aldosterone production: A possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82: 1507–1510
   PubMed Web of Science ®Google Scholar
• Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31: 445–450
   PubMed Web of Science ®Google Scholar
• Pascoe L, Jeunemaitre X, Lebrethon MC, Curnow KM, Gomez-Sanchez CE, Gasc JM, Saez JM, Corvol P. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest 1995; 96: 2236–2246
   PubMed Web of Science ®Google Scholar
• Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999; 84: 4341–4344
   PubMed Web of Science ®Google Scholar
• Stier CT, Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10: 97–107
   PubMedGoogle Scholar
• Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262–265
   PubMed Web of Science ®Google Scholar
• Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89: 8327–8331
   PubMed Web of Science ®Google Scholar
• Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, Gill JR, Jr, Feld L, Ganguly A, Laidlaw JC, Murnagham DJ, Kaufman C, Ulick S, Lalouel JM. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2: 66–74
   PubMed Web of Science ®Google Scholar
• Curnow KM, Mulatero P, Emeric-Blanchouin N, Aupetit-Faisant B, Corvol P, Pascoe L. The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nat Struct Biol 1997; 4: 32–35
   PubMedGoogle Scholar
• Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton R. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001; 138: 715–720
   PubMed Web of Science ®Google Scholar
• Wyckoff JA, Seely EW, Hurwitz S, Anderson BF, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension 2000; 35: 668–672
   PubMed Web of Science ®Google Scholar
• Mulatero P, Morra di Cella S, Williams TA, Milan A, Mengozzi G, Chiandussi L, Gomez-Sanchez CE, Veglio F. Glucocorticoid remediable aldosteronism: Low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 2002; 87: 3187–3191
   PubMed Web of Science ®Google Scholar
• Fallo F, Pilon C, Williams TA, Sonino N, Morra di Cella S, Veglio F, De Iasio R, Montanari P, Mulatero P. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004; 18: 47–51
   PubMed Web of Science ®Google Scholar
• Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60: 48–51
   PubMed Web of Science ®Google Scholar
• Liddle GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20: 1539–1561
   PubMed Web of Science ®Google Scholar
• Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, Boscaro M, Sonino N, Fallo F. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83: 2573–2575
   PubMed Web of Science ®Google Scholar
• Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863–1867
   PubMed Web of Science ®Google Scholar
• Mulatero P, Curnow KM, Aupetit-Faisant B, Foekling M, Gomez-Sanchez CE, Veglio F, Jeunemaitre X, Corvol P, Pascoe L. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J Clin Endocrinol Metab 1998; 83: 3996–4001
   PubMed Web of Science ®Google Scholar
• Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565–571
   PubMed Web of Science ®Google Scholar
• Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820–825
   PubMed Web of Science ®Google Scholar
• DeGasparo M. Antialdosterones: Incidence and prevention of sexual side effects. J Ster Biochem 1989; 32: 223–227
   PubMedGoogle Scholar
• Hoyert DL, Kochanek KD, Murphy SL. Deaths: Final data for 1997. Natl Vital Stat Rep 1999; 47: 1–104
   PubMedGoogle Scholar
• White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–1026
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153
   PubMed Web of Science ®Google Scholar